In a demonstration of the power of green chemistry, scientists are reporting development of a new and more efficient process for making one of the most costly and widely used medications for severe mental illness. Described in a report in the journal ACS Sustainable Chemistry & Engineering, it produces larger amounts of the medication than the existing commercial process while reducing the use of solvents and other potentially toxic substances.
Vijayavitthal T. Mathad and colleagues point out that paliperidone, marketed under the brand name Invega, is one of a new generation of medicines for schizophrenia, a severe form of mental illness. Paliperidone has advantages over other medicines, but the current process for making it is expensive and inefficient, contributing to the drug's cost -- about $18 per tablet in the United States. The process also requires use and disposal of large amounts of solvents that require special handling.
They describe development of a new recipe for making paliperidone. It not only yields larger amounts of the medicine, but uses less solvent and involves an innovative and environmentally friendly method for purifying the medication and for the control and removal of critical impurities that result from the process and carryover from raw materials. The sustainability of the process lies in its capability to withstand the cost pressure when the drug becomes completely generic, the authors said. Reducing the raw material cost not only makes it sustainable but it should be environmentally and production-friendly.
The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 163,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact email@example.com.